Most Read Articles
Pearl Toh, 5 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.
Audrey Abella, 14 Oct 2020
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.

Percutaneous mitral-valve repair appears futile

Jackey Suen
03 Sep 2018
Prof Jean-Francois Obadia (photo credit: European Society of Cardiology)

Percutaneous mitral-valve repair with MitraClip failed to improve clinical outcomes in chronic heart failure (HF) patients with severe secondary mitral regurgitation, according to the MITRA-FR study presented at the European Society of Cardiology (ESC) Congress 2018.

“Our study showed that reduction in mitral regurgitation achieved with percutaneous mitral-valve repair did not translate into a clinical benefit in HF patients,” said principal investigator Professor Jean-Francois Obadia of the Civil Hospices of Lyon, France. “There is no reason to perform this procedure in all HF patients with secondary mitral regurgitation. Further randomized trials are needed to identify subgroups of patients who may benefit from percutaneous mitral-valve repair.”

The study included 304 patients who had symptomatic CHF despite optimal medical therapy, severe secondary mitral regurgitation, left ventricular ejection fraction (LVEF) between 15 percent and 40 percent, and at least one episode of hospitalization for HF within 12 months. They were randomized to undergo percutaneous mitral-valve repair with the MitraClip device plus medical therapy, or medical therapy alone. [N Engl J Med 2018, doi: 10.1056/NEJMoa1805374]

Among patients who were randomized to undergo percutaneous mitral-valve repair with MitraClip, 95.8 percent had the device successfully implanted. At the time of discharge from hospital, 95.1 percent of patients had a reduction in mitral regurgitation severity of at least one grade, 91.9 percent had reduction of mitral regurgitation severity to grade 2+ or lower, and 75.6 percent had reduction to grade 0+ to 1+. The procedure was generally safe.

In the intent-to-treat population, the composite primary endpoint of all-cause mortality or unplanned rehospitalization for HF at 12 months failed to demonstrate a significant difference favouring percutaneous mitral-valve repair plus medical therapy vs medical therapy alone (54.6 percent vs 51.3 percent; odds ratio, 1.16; 95 percent confidence interval [CI], 0.73 to 1.84; p=0.53). The rate of all-cause death was 24.3 percent in patients receiving percutaneous mitral-valve repair plus medical therapy vs 22.4 percent in those receiving medical therapy alone (p=0.66), while the rate of HF rehospitalization was 48.7 percent vs 47.4 percent (p=0.47). Similar findings were noted in the per-protocol analysis.

“The results were also similar across all prespecified subgroups, including patients with LVEF <30 percent vs ≥30 percent, as well as those with mitral regurgitant orifice <30 mm2 vs 30-40 mm2 vs >40 mm2,” added Obadia.

Prospective registry studies suggest that percutaneous mitral-valve repair can reduce symptoms and improve functional capacity and quality of life in patients with secondary mitral regurgitation. However, it has remained uncertain whether adding percutaneous mitral-valve repair to medical treatment has a beneficial effect on hard clinical outcomes.

“The MITRA-FR study showed that percutaneous correction of secondary mitral regurgitation was safe and effective, but failed to translate into improved outcomes,” concluded Obadia. “This suggests that the poor clinical outcomes in this patient population is more due to the underlying cardiomyopathy than mitral regurgitation. Mitral regurgitation is probably just a marker of severity.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.
Audrey Abella, 14 Oct 2020
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.